Loading clinical trials...
Loading clinical trials...
In Hospital and Long Term Outcomes After Recurrent Ventricular Arrythmias
Electrical storm (ES) is a life-threatening syndrome defined by the recurrence of ventricular arrythmias. ES is also represented by a wide spectrum of clinical situations ranging from recurrent monomorphic VT reduced by anti-tachycardia pacing (ATP) in relatively stable patients to recurrent VF in hemodynamically unstable patients. Thus, the purpose of this study was to assess the incidence and predictors of long term mortality following hospitalization in the intensive care unit for ES, in a large retrospective multicentric study.
Electrical storm (ES) is a life-threatening syndrome defined by the recurrence of ventricular arrythmias) and commonly occurs in implantable cardioverter defibrillator (ICD) recipients with an incidence ranging from 10 to 58% for secondary prevention. ES is also represented by a wide spectrum of clinical situations ranging from recurrent monomorphic VT reduced by anti-tachycardia pacing (ATP) in relatively stable patients to recurrent VF in hemodynamically unstable patients. Furthermore, ES can occur in the setting of acute reversible factors and/or underlying advanced structural heart disease. This wide clinical spectrum leads to major implications in ES management. Although several studies have focused on the predictors of ES and associated mortality, especially in the setting of VT ablation, only limited data assessing predictors of mortality following ES, are available. Thus, the purpose of this study was to assess the incidence and predictors of long term mortality following hospitalization in the intensive care unit for ES, in a large retrospective multicentric study.
Age
18 - 90 years
Sex
ALL
Healthy Volunteers
No
Start Date
July 1, 2025
Primary Completion Date
September 30, 2025
Completion Date
October 15, 2025
Last Updated
June 24, 2025
300
ESTIMATED participants
Lead Sponsor
Central Hospital, Nancy, France
Collaborators
NCT04419480
NCT06080074
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions